Statins in Very Elderly Adults (Debate)

Neil J. Stone, MD, MACP, FACC; Sunny Intwala, MD; Dan Katz, BA


J Am Geriatr Soc. 2014;62(5):943-945. 

In This Article


The Justification for the Use of Statins in Prevention: An Interventional Trial Evaluating Rosuvastatin primary prevention trial illustrated the ASCVD benefit versus metabolic risk. For every 134 vascular events or deaths avoided, 54 new cases of diabetes mellitus were diagnosed. Moreover, impaired fasting glucose greater than 100 mg/dL, glycosylated hemoglobin level of 6% or greater, three or more components of the metabolic syndrome and body mass index of 30.0 kg/m2 or greater predicted development of diabetes mellitus with statin therapy: the larger the tally, the greater the risk of diabetes mellitus.[6] These data indicate that those who are most likely to progress to diabetes mellitus are at greater risk already, although the Cholesterol Treatment Trialists data attest to striking ASCVD benefits from statin therapy even with new-onset diabetes mellitus.